Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free VRPX Stock Alerts

Virpax Pharmaceuticals (VRPX) Competitors

Virpax Pharmaceuticals logo
$0.0002 0.00 (0.00%)
As of 10/9/2026
Compare

VRPX vs. CMND, BPTSY, IMCC, SRNE, and PRPH

Should you buy Virpax Pharmaceuticals stock or one of its competitors? Virpax Pharmaceuticals's main competitors and comparable companies include Clearmind Medicine (CMND), Biophytis (BPTSY), IM Cannabis (IMCC), Sorrento Therapeutics (SRNE), and ProPhase Labs (PRPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Virpax Pharmaceuticals compare to Clearmind Medicine?

Clearmind Medicine (NASDAQ:CMND) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Clearmind Medicine's return on equity of -88.53% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -88.53% -61.62%
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

In the previous week, Clearmind Medicine had 8 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 8 mentions for Clearmind Medicine and 0 mentions for Virpax Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.61 beat Virpax Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Positive
Virpax Pharmaceuticals Neutral

Clearmind Medicine is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Clearmind Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -214.69, indicating that its share price is 21,569% less volatile than the broader market.

Summary

Clearmind Medicine beats Virpax Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Biophytis?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Biophytis (NASDAQ:BPTSY) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Biophytis' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Biophytis N/A N/A N/A

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Biophytis Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
BiophytisN/AN/A-$18.43MN/AN/A

Virpax Pharmaceuticals has a beta of -214.69, meaning that its share price is 21,569% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Biophytis beats Virpax Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to IM Cannabis?

Virpax Pharmaceuticals (NASDAQ:VRPX) and IM Cannabis (NASDAQ:IMCC) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Virpax Pharmaceuticals has a beta of -214.69, suggesting that its share price is 21,569% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virpax Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

IM Cannabis has higher revenue and earnings than Virpax Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
IM Cannabis$39.17M0.01-$8.10M-$60.66N/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, IM Cannabis had 3 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Virpax Pharmaceuticals. IM Cannabis' average media sentiment score of 0.16 beat Virpax Pharmaceuticals' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the news media.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
IM Cannabis Neutral

Virpax Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. IM Cannabis' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
IM Cannabis -39.62%N/A -58.32%

Summary

IM Cannabis beats Virpax Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Sorrento Therapeutics?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Sorrento Therapeutics (NASDAQ:SRNE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Virpax Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Sorrento Therapeutics$60.32M0.00-$572.84MN/AN/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Virpax Pharmaceuticals has a beta of -214.69, suggesting that its stock price is 21,569% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Sorrento Therapeutics Neutral

Sorrento Therapeutics' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Sorrento Therapeutics N/A N/A N/A

Summary

Virpax Pharmaceuticals and Sorrento Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to ProPhase Labs?

ProPhase Labs (NASDAQ:PRPH) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ProPhase Labs had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for ProPhase Labs and 0 mentions for Virpax Pharmaceuticals. ProPhase Labs' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
ProPhase Labs Neutral
Virpax Pharmaceuticals Neutral

Virpax Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ProPhase Labs-825.01% -482.05% -88.90%
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

ProPhase Labs has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -214.69, meaning that its share price is 21,569% less volatile than the broader market.

Virpax Pharmaceuticals has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProPhase Labs$5.06M0.03-$53.36M-$2.25N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Summary

ProPhase Labs beats Virpax Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRPX vs. The Competition

Export
MetricVirpax PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.40B$7.25B$13.30B
Dividend YieldN/A2.63%2.52%22.58%
P/E Ratio0.00797.58275.2926.14
Price / SalesN/A751.21576.8585.23
Price / CashN/A86.6676.9653.71
Price / Book0.0010.7111.226.33
Net Income-$15.19M$2.84B$3.50B$382.15M
7 Day PerformanceN/A-0.94%-0.89%-1.40%
1 Month PerformanceN/A-3.67%-4.02%-3.35%
1 Year PerformanceN/A-3.97%7.13%1.49%

Virpax Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
N/A$0.00
flat		N/AN/A$0.00N/AN/A7
CMND
Clearmind Medicine
1.0241 of 5 stars		$0.74
-8.6%		N/A-99.8%$757KN/AN/A4
BPTSY
Biophytis
N/A$0.25
flat		N/AN/A$586KN/AN/A30
IMCC
IM Cannabis
0.1846 of 5 stars		$2.24
-0.5%		N/A-97.3%$476K$39.17MN/A44
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-86.7%$441K$60.32MN/A949

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRPX) was last updated on 10/11/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel